Nikoloas Papachristou1, Payam Barnaghi1, Bruce A Cooper2, Xiao Hu2, Roma Maguire3, Kathi Apostolidis4, Jo Armes5, Yvette P Conley6, Marilyn Hammer7, Stylianos Katsaragakis8, Kord M Kober2, Jon D Levine9, Lisa McCann3, Elisabeth Patiraki10, Steven M Paul2, Emma Ream1, Fay Wright11, Christine Miaskowski12. 1. School of Health Sciences, University of Surrey, Guilford, UK. 2. School of Nursing, University of California, San Francisco, California, USA. 3. Department of Computer and Information Sciences, University of Strathclyde, Glasgow, UK. 4. European Cancer Patient Coalition, Brussels, Belgium. 5. Florence Nightingale Faculty of Nursing and Midwifery, King's College, London, UK. 6. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 7. Department of Nursing, Mount Sinai Medical Center, New York, New York, USA. 8. Faculty of Nursing, University of Peloponnese, Efstathiou & Stamatikis Valioti and Plateon, PC, Sparti, Greece. 9. School of Medicine, University of California, San Francisco, California, USA. 10. School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece. 11. School of Nursing, Yale University, New Haven, Connecticut, USA. 12. School of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
Abstract
CONTEXT: Risk profiling of oncology patients based on their symptom experience assists clinicians to provide more personalized symptom management interventions. Recent findings suggest that oncology patients with distinct symptom profiles can be identified using a variety of analytic methods. OBJECTIVES: The objective of this study was to evaluate the concordance between the number and types of subgroups of patients with distinct symptom profiles using latent class analysis and K-modes analysis. METHODS: Using data on the occurrence of 25 symptoms from the Memorial Symptom Assessment Scale, that 1329 patients completed prior to their next dose of chemotherapy (CTX), Cohen's kappa coefficient was used to evaluate for concordance between the two analytic methods. For both latent class analysis and K-modes, differences among the subgroups in demographic, clinical, and symptom characteristics, as well as quality of life outcomes were determined using parametric and nonparametric statistics. RESULTS: Using both analytic methods, four subgroups of patients with distinct symptom profiles were identified (i.e., all low, moderate physical and lower psychological, moderate physical and higher Psychological, and all high). The percent agreement between the two methods was 75.32%, which suggests a moderate level of agreement. In both analyses, patients in the all high group were significantly younger and had a higher comorbidity profile, worse Memorial Symptom Assessment Scale subscale scores, and poorer QOL outcomes. CONCLUSION: Both analytic methods can be used to identify subgroups of oncology patients with distinct symptom profiles. Additional research is needed to determine which analytic methods and which dimension of the symptom experience provide the most sensitive and specific risk profiles.
CONTEXT: Risk profiling of oncology patients based on their symptom experience assists clinicians to provide more personalized symptom management interventions. Recent findings suggest that oncology patients with distinct symptom profiles can be identified using a variety of analytic methods. OBJECTIVES: The objective of this study was to evaluate the concordance between the number and types of subgroups of patients with distinct symptom profiles using latent class analysis and K-modes analysis. METHODS: Using data on the occurrence of 25 symptoms from the Memorial Symptom Assessment Scale, that 1329 patients completed prior to their next dose of chemotherapy (CTX), Cohen's kappa coefficient was used to evaluate for concordance between the two analytic methods. For both latent class analysis and K-modes, differences among the subgroups in demographic, clinical, and symptom characteristics, as well as quality of life outcomes were determined using parametric and nonparametric statistics. RESULTS: Using both analytic methods, four subgroups of patients with distinct symptom profiles were identified (i.e., all low, moderate physical and lower psychological, moderate physical and higher Psychological, and all high). The percent agreement between the two methods was 75.32%, which suggests a moderate level of agreement. In both analyses, patients in the all high group were significantly younger and had a higher comorbidity profile, worse Memorial Symptom Assessment Scale subscale scores, and poorer QOL outcomes. CONCLUSION: Both analytic methods can be used to identify subgroups of oncology patients with distinct symptom profiles. Additional research is needed to determine which analytic methods and which dimension of the symptom experience provide the most sensitive and specific risk profiles.
Authors: Marylin J Dodd; Maria H Cho; Bruce A Cooper; Judy Petersen; Kayee Alice Bank; Kathryn A Lee; Christine Miaskowski Journal: Oncol Nurs Forum Date: 2011-01 Impact factor: 2.172
Authors: Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden Journal: J Natl Cancer Inst Date: 2017-01-24 Impact factor: 13.506
Authors: Jennifer Barsky Reese; Amanda Blackford; Jonathan Sussman; Toru Okuyama; Tatsuo Akechi; Daryl Bainbridge; Doris Howell; Claire F Snyder Journal: Qual Life Res Date: 2014-01-31 Impact factor: 4.147
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Karine A S L Ferreira; Miako Kimura; Manoel J Teixeira; Tito R Mendoza; Jose Cláudio M da Nóbrega; Silvia R Graziani; Teresa Yae Takagaki Journal: J Pain Symptom Manage Date: 2008-03-24 Impact factor: 3.612
Authors: Kirsten K Ness; Kevin R Krull; Kendra E Jones; Daniel A Mulrooney; Gregory T Armstrong; Daniel M Green; Wassim Chemaitilly; Webb A Smith; Carmen L Wilson; Charles A Sklar; Kyla Shelton; Deo Kumar Srivastava; Sabeen Ali; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Maria Tejada; Carol Viele; Kord M Kober; Bruce A Cooper; Steven M Paul; Laura B Dunn; Marilyn J Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Nikolaos Papachristou; Payam Barnaghi; Bruce Cooper; Kord M Kober; Roma Maguire; Steven M Paul; Marilyn Hammer; Fay Wright; Jo Armes; Eileen P Furlong; Lisa McCann; Yvette P Conley; Elisabeth Patiraki; Stylianos Katsaragakis; Jon D Levine; Christine Miaskowski Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Komal P Murali; Gary Yu; John D Merriman; Allison Vorderstrasse; Amy S Kelley; Abraham A Brody Journal: Nurs Res Date: 2021 Nov-Dec 01 Impact factor: 2.381
Authors: Arnold L Potosky; Kristi D Graves; Li Lin; Wei Pan; Jane M Fall-Dickson; Jaeil Ahn; Kristin M Ferguson; Theresa H M Keegan; Lisa E Paddock; Xiao-Cheng Wu; Rosemary Cress; Bryce B Reeve Journal: J Cancer Surviv Date: 2021-11-17 Impact factor: 4.062
Authors: Lissi Hansen; Michael F Chang; Shirin Hiatt; Nathan F Dieckmann; Arnab Mitra; Karen S Lyons; Christopher S Lee Journal: Clin Gastroenterol Hepatol Date: 2021-11-20 Impact factor: 13.576
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Laura B Dunn; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-10-17 Impact factor: 3.612
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Kord M Kober; Marilyn J Hammer; Fay Wright; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2021-01-16 Impact factor: 3.359
Authors: Tara L Kaufmann; Kelly D Getz; Jesse Y Hsu; Antonia V Bennett; Samuel U Takvorian; Arif H Kamal; Angela DeMichele Journal: JCO Oncol Pract Date: 2021-03-24
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022 Mar-Apr 01 Impact factor: 2.592